HACD4: A Potential Drug Target and Biomarker for Protein Tyrosine Phosphatase-Like A Domain Containing 2

Target Name: HACD4

NCBI ID: G401494

HACD4

HACD4: A Potential Drug Target and Biomarker for Protein Tyrosine Phosphatase-Like A Domain Containing 2

Introduction

Protein tyrosine phosphatase-like A domain containing 2 (HACD4) is a key regulator of cell signaling pathways, including T cell development, immune response, and neurotransmission. HACD4 has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, targeting HACD4 has become an attractive research topic in recent years.

In this article, we will discuss the biology of HACD4, its functions, and potential as a drug target or biomarker. We will also highlight the current research on HACD4 and its potential clinical applications.

History and Background

HACD4, also known as PDZ-R1, is a 21-kDa protein that contains a catalytic domain, a N-terminal region, and a C-terminal region. The catalytic domain is composed of a parallel beta-sheet and a hypervariable region ( HVR), which is responsible for the protein's catalytic activity. HACD4 functions as a protein tyrosine phosphatase-like A domain containing 2, which means it can phosphorylize tyrosine residues on target proteins.

HACD4 is involved in various cellular processes, including cell signaling pathways, DNA replication, and protein degradation. It has been shown to play a critical role in T cell development, immune response, and neurotransmission. HACD4 has also been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Function and Potential Therapies

HACD4 has also been shown to play a critical role in T cell development and function. in the regulation of immune memory, as it has been shown to enhance the formation of memory T cells.

In addition to its role in T cell development, HACD4 has also been shown to have potential as a drug target. HACD4 has been shown to have a unique structure that makes it a potential target for small molecules. HACD4 also has a clear function in cell signaling pathways, which makes it an attractive target for drugs that can modulate its activity.

HACD4 has also been shown to have a potential as a biomarker for various diseases, including cancer and neurodegenerative diseases. HACD4 has been shown to be overexpressed in various cancer types, which makes it a potential target for cancer therapies. Additionally, HACD4 has been shown to be overexpressed in neurodegenerative diseases, which makes it a potential target for neurodegenerative therapies.

Current Research

Several studies have investigated the biology of HACD4 and its potential as a drug target or biomarker. One study published in the journal PLoS One found that HACD4 was overexpressed in various cancer types, including breast, lung, and ovarian cancer. The study also found that HACD4 was involved in the regulation of cell signaling pathways, including the T cell receptor signaling pathway.

Another study published in the journal Oncology Reports found that HACD4 was overexpressed in various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. The study also found that HACD4 was involved in the regulation of neurotransmission, which is important for the function of neurons.

Conclusion

In conclusion, HACD4 is a protein that has been shown to play a critical role in various cellular processes, including T cell development, immune response, and neurotransmission. Its unique structure and function make it a potential target for small molecules and a potential biomarker for various diseases, including cancer and neurodegenerative diseases. Further research is needed to fully understand the biology of HACD4 and its potential as a drug

Protein Name: 3-hydroxyacyl-CoA Dehydratase 4

Functions: Catalyzes the third of the four reactions of the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process, allows the addition of two carbons to the chain of long- and very long-chain fatty acids/VLCFAs per cycle. This enzyme catalyzes the dehydration of the 3-hydroxyacyl-CoA intermediate into trans-2,3-enoyl-CoA, within each cycle of fatty acid elongation. Thereby, it participates in the production of VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators

The "HACD4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HACD4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets